Immunogenicity of infliximab in Crohn's disease.
Hanauer
Stephen B
SB
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000906:Antibodies / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab